• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Addresses Rare Disease Trial Challenges in Revised Draft Guidance

FDA Addresses Rare Disease Trial Challenges in Revised Draft Guidance

January 21, 2019
William Myers

A new draft guidance on rare disease trials may help sponsors ease the tensions between the need for robust, scientifically sound data and the small patient populations that they’re hoping to treat.

The guidance offers sponsors advice on filling the gap by using such tools as natural histories, surrogate biomarkers, external controls and early randomization but perhaps most importantly, offers a new section on safety.

Lindsay McNair, chief medical officer of WCG Clinical, says the guidance “synthesizes and updates information for the sponsors and researchers working in these therapeutic areas and addresses some of the issues that are frequently challenging.”

“I would say that the challenge in developing new therapies for rare diseases is that it often involves a lot of groundbreaking with little regulatory precedent and challenges in the study design, such as determining what the appropriate endpoints will be,” McNair says.

In the new section on drug safety, the guidance encourages sponsors to come up with their own ideas for rare disease safety data, but also offers some suggestions on common approaches.

Drug sponsors should consider natural histories, trial eligibility, dose selection, computer arms or auxiliary safety cohorts as means to ensure that they’re giving regulators the best — and most — possible safety data for rare disease treatments, the draft says.

Canvassing possible approaches to expanded safety data, the agency says of each:

  • Natural histories can “help distinguish drug-related adverse effects from underlying disease manifestations;”
  • Trial eligibility: sponsors should “consider enrichment strategies to decrease heterogeneity and to enhance the ability of the clinical trial to demonstrate a potential treatment effect;”
  • Attention to dose selection is important to make sure that patients don’t stop taking medicines because their doses are too low or high; and
  • Auxiliary cohorts can include a trial protocol with a parallel safety cohort (alongside an efficacy trial), a trial that gives patients drugs under expanded access or gathers relevant data from other sources, such as trials using the drug for another purpose or studies of similar drugs.

When considering a rare disease drug’s feasibility — which also can be tough, given the small populations involved — sponsors should include all the disease’s permutations through different life stages of its patients.

“Sponsors also should determine prevalence estimates for all countries in which trial sites are being considered,” the document states. “Sponsors should provide the individual sources of current published prevalence estimates, rather than calculated averages, because published prevalence estimates can vary widely depending on study details ... country or region, and advances in diagnostics and treatment over time.”

You can read the FDA’s new draft guidance here: https://bit.ly/2FAUUr6.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing